Abstract
PIGA mutations in paroxysmal nocturnal hemoglobinuria (PNH) patients lead to a glycosylphosphatidylinositol (GPI)-linked membrane proteins expression deficiency. Herein, we report the constitutive expression of the transmembrane CD160 (CD160-TM) activating receptor on non PIGA-mutated PNH patients circulating NK cells. In healthy individuals, only the GPI-anchored isoform of CD160 receptors is expressed on the circulating NK lymphocytes, while the transmembrane isoform appears after ex vivo activation. Similarly to CD160-GPI, we identified CD160-TM as a receptor for the MHC class I molecules. We demonstrate that PNH patients NK lymphocytes spontaneously produce significant amounts of IFN-γ that is inhibited by anti-CD160-TM or anti-MHC class I mAbs. These results indicate that circulating NK cells from PNH patients exhibit a self-MHC class I molecule reactive effector function, which could be mediated through the recruitment of CD160-TM receptor. Our data provide new insights regarding the possible role of CD160-TM on PNH patients NK lymphocytes and in the pathogenesis of the disease
Keywords: Anchored CD160, NK lymphocytes, paroxysmal nocturnal hemoglobinuria, transmembrane, polymorphic genes, haplotypes, apoptosis, signaling pathway, hematopoietic stem cells, mutations, idiopathic aplastic anemia, hypoplastic myelodysplastic syndrome, Eculizumab, thrombocytopenia, immunosuppressive therapy
Current Molecular Medicine
Title: Possible Pathogenic Role of the Transmembrane Isoform of CD160 NK Lymphocyte Receptor in Paroxysmal Nocturnal Hemoglobinuria
Volume: 12 Issue: 2
Author(s): J. Giustiniani, S. Sabour-Alaoui, J. Bernard, D. Olive, C. Bos, A. Razafindratsita, A. Petropoulou, R.P. de Latour, P. Le Bouteiller, M. Bagot, G. Socie, A. Bensussan and A. Marie-Cardine
Affiliation:
Keywords: Anchored CD160, NK lymphocytes, paroxysmal nocturnal hemoglobinuria, transmembrane, polymorphic genes, haplotypes, apoptosis, signaling pathway, hematopoietic stem cells, mutations, idiopathic aplastic anemia, hypoplastic myelodysplastic syndrome, Eculizumab, thrombocytopenia, immunosuppressive therapy
Abstract: PIGA mutations in paroxysmal nocturnal hemoglobinuria (PNH) patients lead to a glycosylphosphatidylinositol (GPI)-linked membrane proteins expression deficiency. Herein, we report the constitutive expression of the transmembrane CD160 (CD160-TM) activating receptor on non PIGA-mutated PNH patients circulating NK cells. In healthy individuals, only the GPI-anchored isoform of CD160 receptors is expressed on the circulating NK lymphocytes, while the transmembrane isoform appears after ex vivo activation. Similarly to CD160-GPI, we identified CD160-TM as a receptor for the MHC class I molecules. We demonstrate that PNH patients NK lymphocytes spontaneously produce significant amounts of IFN-γ that is inhibited by anti-CD160-TM or anti-MHC class I mAbs. These results indicate that circulating NK cells from PNH patients exhibit a self-MHC class I molecule reactive effector function, which could be mediated through the recruitment of CD160-TM receptor. Our data provide new insights regarding the possible role of CD160-TM on PNH patients NK lymphocytes and in the pathogenesis of the disease
Export Options
About this article
Cite this article as:
Giustiniani J., Sabour-Alaoui S., Bernard J., Olive D., Bos C., Razafindratsita A., Petropoulou A., de Latour R.P., Le Bouteiller P., Bagot M., Socie G., Bensussan A. and Marie-Cardine A., Possible Pathogenic Role of the Transmembrane Isoform of CD160 NK Lymphocyte Receptor in Paroxysmal Nocturnal Hemoglobinuria, Current Molecular Medicine 2012; 12 (2) . https://dx.doi.org/10.2174/156652412798889081
DOI https://dx.doi.org/10.2174/156652412798889081 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biological Denitrification: Screening of Packing Material, Comparison of Denitrification Rate by Pseudomonas aeruginosa and Pseudomonas stutzeri, Application and Design of Bioreactor
Current Environmental Engineering c-Myc: Linking Transformation and Genomic Instability
Current Molecular Medicine MicroRNAs Regulate the Epithelial to Mesenchymal Transition (EMT) in Cancer Progression
MicroRNA The Use of Innovative Tools to Reproduce Human Cancer Translocations: Lessons from the CRISPR/Cas System
Current Biotechnology In Vivo Space Radiation-Induced Non-Targeted Responses: Late Effects on Molecular Signaling in Mitochondria
Current Molecular Pharmacology The Proteasome as a Therapeutic Target for Lung Fibrosis
Current Enzyme Inhibition Anticancer Vitamin K3 Analogs: A Review
Anti-Cancer Agents in Medicinal Chemistry Hybrid Molecules Development: A Versatile Landscape for the Control of Antifungal Drug Resistance: A Review
Mini-Reviews in Medicinal Chemistry Monoclonal Antibodies: New Therapeutic Agents for Autoimmune Hemolytic Anemia?
Endocrine, Metabolic & Immune Disorders - Drug Targets Insertional Mutagenesis by Retroviral Vectors: Current Concepts and Methods of Analysis
Current Gene Therapy Anti-CD30 Human IL-2 Fusion Proteins Display Strong and Specific Cytotoxicity In Vivo
Current Drug Targets Curcumin and Liver Cancer: A Review
Current Pharmaceutical Biotechnology Design of Peptide-Based Vaccines for Cancer
Current Medicinal Chemistry The Immunoproteasome as a Therapeutic Target for Hematological Malignancies
Current Cancer Drug Targets Biotechnological Approaches for the Treatment of Inflammatory Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Epigenetic Mismatches with Mutated Transcribing Genes at Leukemogenic S-Phase Binding/Start Sites – Potential Targets for Therapy with Enzyme Inhibitors
Current Stem Cell Research & Therapy A Systems Biology Road Map for the Discovery of Drugs Targeting Cancer Cell Metabolism
Current Pharmaceutical Design The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development
Current Molecular Medicine Comprehensive DNA Methylation-transcriptome Profiles Association Analysis During the Treatment of Acute Myelocytic Leukemia
Current Pharmaceutical Design Synthesis of [<sup>64</sup>Cu]Cu-NOTA-Bn-GE11 for PET Imaging of EGFR-Rich Tumors
Current Radiopharmaceuticals